# Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

> **NCT05070364** · PHASE3 · UNKNOWN · sponsor: **Eiger BioPharmaceuticals** · enrollment: 150 (estimated)

## Conditions studied

- Hepatitis Delta Virus

## Interventions

- **DRUG:** Peginterferon Lambda-1a

## Key facts

- **NCT ID:** NCT05070364
- **Lead sponsor:** Eiger BioPharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-21
- **Primary completion:** 2024-06-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05070364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05070364, "Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05070364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*